Pulmonary Drug Delivery has been a controversial method since its inception. There are many reasons why this method should be reviewed before being implemented. First and foremost, it poses a serious threat to the patient's general health. Due to the very limited amount of drug trans-reactions in the lungs, delivery of trans-bioids poses a much higher risk compared to other methods such as IV administration. Also, lungs have a very complex defense system in order to remove inhaled drug particulates from them and once deposited there.
There is no perfect Pulmonary Drug Delivery system. The efficiency of the system will be dependent on the physical condition of the patient, the equipment utilized, and the expertise of the person administering the treatment and monitoring the vital signs. It has been found that Pulmonary-gas-prilosec delivery is more effective when administered by expert medical staff working in a hospital. This is because the equipment required for this process is expensive. However, in rural or informal settings, when the possibility of contamination of intravenous drugs is not a big concern, the equipment needed is not as expensive.
There are two types of Pulmonary Drug Delivery Systems; Extracorporeal and Intravenous (IV) administration. In the former, a single dose of a drug is administered through an infusion pump, which contains either plastic tubing or glass ampoules filled with the drug. These are connected to a ventilator to prevent air blockage during transport of the drug into the lungs. The intramuscular injection of drugs is not as common because it makes use of a needle into a muscle, which causes the drug to be introduced into the circulatory system by introducing it directly into the bloodstream. Although intramuscular therapy is more efficient than the portable tube pump used in Pulmonary-drug delivery, it can cause discomfort in some patients and may cause allergic reactions in others. Intravenous therapy is generally recommended as first-line therapy for patients receiving Pulmonary-gas-Prilosec treatment.
Other Pulmonary-drug delivery systems include the combined oral immunoglobulin, or IgG, and intramuscularly injected drugs (IMIDs). Immune globulins or GMP are protein complexes that stimulate the immune system and increase its ability to protect the body from infection. These complexes prevent bacteria from attaching to the lining of the lungs and interfering with breathing. IGRs are commonly combined with levorotriptan or interferon-gamma, an anti-viral agent that is sometimes used in severe diseases such as HIV/AIDS and cancer. IMIDs include a combination of interferon-gamma and aspirin, which help reduce the gastrointestinal tract inflammation caused by drug delivery.
Nanocarrier technology is another emerging pulmonary targeted drug delivery system. Nanocarriers are drug delivery vehicles made entirely of nanotechnology, whereby drugs are delivered into the body through the use of ultrasound waves. Unlike IGRs, which are delivered via the bloodstream, these drugs circulate in the body's fluids. However, unlike IGRs, when a harmful disease is contracted, the nanocarrier will first stop the harmful particles from circulating in the body fluid, before being injected into the affected tissue. Although there is still much research to be done on these new delivery vehicles, the early results have been promising.
No comments:
Post a Comment